Project Grant HT94252510320
Award Date
5/1/25
Completion Date
4/30/27
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This $682,472 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to selectively target mutant SHP2 oncoproteins in rare leukemias. The award will fund SBP's efforts to advance understanding of the fundamental mechanisms of disease and develop innovative therapies, with a focus on areas such as cancer, aging, neurodegenerative...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $571,350.00 in funding to the Sanford Burnham Prebys Medical Discovery Institute (SBP) in La Jolla, California. The award supports research aimed at developing metabolic interventions to halt the progression of pancreatic cancer. SBP, an independent non-profit biomedical research organization, will leverage advanced technologies and...
The federal Project Grant award of $974,355.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sanford Burnham Prebys Medical Discovery Institute. The award supports a research project entitled "WHITE ADIPOSE TISSUE SURROUNDING LYMPH NODES MODULATES ANTIMELANOMA IMMUNITY" with a performance period from July 1, 2024 to June 30, 2027. The funding will enable the Sanford Burnham Prebys Medical Discovery...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This federal Project Grant award, valued at $2,180,261.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Projenx Inc., a small disadvantaged business located in New York, NY. The purpose of the award is to conduct a Phase 1C study of Prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with amyotrophic lateral sclerosis (ALS). The study will run from April 1, 2025 to March 31, 2027, with the goal of...
The University of California, San Diego (UCSD) was awarded a $2,179,391 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct proof-of-concept preclinical studies and GMP development of AAV-SynCav1 gene technology to treat amyotrophic lateral sclerosis (ALS). The award, which began on May 1, 2024, will support research and development efforts aimed at advancing a novel gene therapy approach to address this debilitating...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
The U.S. Defense Health Agency awarded a $1,979,313 project grant to Sachi Bioworks, Inc., a self-certified small disadvantaged business located in Erie, Colorado, to develop a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). This grant, provided under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports Sachi Bioworks' advanced biotechnology research and development efforts focused on innovative drug discovery...
The University of California, San Diego received a $694,650 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The two-year award will support research on RNA-directed therapy for amyotrophic lateral sclerosis (ALS) linked to the C9ORF72 gene using engineered zinc finger nucleases. The Military Medical Research and Development program aims to transform military and public health through...